Erratum: Downregulation of NOB1 suppresses the proliferation and tumor growth of non-small cell lung cancer in vitro and in vivo (Oncology Reports (2014) 31 (1271-1276) DOI:10.3892/or.2014.2991);Downregulation of NOB1 suppresses the proliferation and tumor growth of non-small cell lung cancer in vitro and in vivo

Oncology Reports

Volumn 31, Issue 3, 2014, Pages 1271-1276

  Li, Yang ^a   Ma, Chengyuan ^a   Qian, Ming ^b   Wen, Zhongmei ^a   Jing, Hongyu ^a   Qian, Donghua ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

NOB1; Non small cell lung cancer; RNA silencing; Tumorigenesis

Indexed keywords

NIN1 RPN12 BINDING PROTEIN 1 HOMOLOGUE; SHORT HAIRPIN RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER STAGING; CELL CYCLE G0 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; EXPRESSION VECTOR; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NOB1 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE; TUMOR GROWTH; UPREGULATION;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN D3; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS;

EID: 84896732053     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2020.7483     Document Type: Erratum

References (29)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer 13: 252-266, 2012.
3. Schiller JH: Small cell lung cancer: defining a role for emerging platinum drugs. Oncology 63: 105-114, 2002.
4. Stinchcombe TE and Socinski MA: Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. J Thorac Oncol 4: 243-250, 2009.
5. Ramalingam S and Belani CP: Recent advances in targeted therapy for non-small cell lung cancer. Expert Opin Ther Targets 11: 245-257, 2007. (Pubitemid 46188817)
6. Zhang Y, Ni J, Zhou G, et al: Cloning, expression and characterization of the human NOB1 gene. Mol Biol Rep 32: 185-189, 2005. (Pubitemid 41374360)
7. Makarova KS, Aravind L, Galperin MY, et al: Comparative genomics of the Archaea (Euryarchaeota): evolution of conserved protein families, the stable core, and the variable shell. Genome Res 9: 608-628, 1999. (Pubitemid 29377980)
8. Arcus VL, Backbro K, Roos A, Daniel EL and Baker EN: Distant structural homology leads to the functional characterization of an archaeal PIN domain as an exonuclease. J Biol Chem 279: 16471-16478, 2004. (Pubitemid 38509345)
9. Lamanna AC and Karbstein K: Nob1 binds the single-stranded cleavage site D at the 3′-end of 18S rRNA with its PIN domain. Proc Natl Acad Sci USA 106: 14259-14264, 2009.
10. Fatica A, Tollervey D and Dlakic M: PIN domain of Nob1p is required for D-site cleavage in 20S pre-rRNA. RNA 10: 1698-1701, 2004. (Pubitemid 39426368)
11. Fatica A, Oeffinger M, Dlakic M and Tollervey D: Nob1p is required for cleavage of the 3′ end of 18S rRNA. Mol Cell Biol 23: 1798-1807, 2003. (Pubitemid 36246059)
12. Huang WY, Chen DH, Ning L and Wang LW: siRNA mediated silencing of NIN1/RPN12 binding protein 1 homolog inhibits proliferation and growth of breast cancer cells. Asian Pac J Cancer Prev 13: 1823-1827, 2012.
13. Lu Z, Guo Q, Shi A, Xie F and Lu Q: Downregulation of NIN/ RPN12 binding protein inhibits the growth of human hepatocellular carcinoma cells. Mol Biol Rep 39: 501-507, 2012.
14. Lin Y, Peng S, Yu H, Teng H and Cui M: RNAi-mediated downregulation of NOB1 suppresses the growth and colony-formation ability of human ovarian cancer cells. Med Oncol 29: 311-317, 2012.
15. Wu DP and He XW: Expression of NOB1 and its significance in colorectal cancer. Nan Fang Yi Ke Da Xue Xue Bao 32: 420-422, 2012 (in Chinese).
16. Lin S, Meng W, Zhang W, et al: Expression of the NOB1 gene and its clinical significance in papillary thyroid carcinoma. J Int Med Res 41: 568-572, 2013.
17. Oehler VG, Yeung KY, Choi YE, Bumgarner RE, Raftery AE and Radich JP: The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 114: 3292-3298, 2009.
18. Granneman S, Nandineni MR and Baserga SJ: The putative NTPase Fap7 mediates cytoplasmic 20S pre-rRNA processing through a direct interaction with Rps14. Mol Cell Biol 25: 10352-10364, 2005. (Pubitemid 41681960)
19. Ramos PC, Hockendorff J, Johnson ES, Varshavsky A and Dohmen RJ: Ump1p is required for proper maturation of the 20S proteasome and becomes its substrate upon completion of the assembly. Cell 92: 489-499, 1998. (Pubitemid 28101112)
20. Raychaudhuri S, Fontanes V, Barat B and Dasgupta A: Activation of ribosomal RNA transcription by hepatitis C virus involves upstream binding factor phosphorylation via induction of cyclin D1. Cancer Res 69: 2057-2064, 2009.
21. Meraner J, Lechner M, Loidl A, et al: Acetylation of UBF changes during the cell cycle and regulates the interaction of UBF with RNA polymerase I. Nucleic Acids Res 34: 1798-1806, 2006.
22. Shirane M, Harumiya Y, Ishida N, et al: Down-regulation of p27Kip1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem 274: 13886-13893, 1999. (Pubitemid 129518688)
23. Xu G, Bernaudo S, Fu G, Lee DY, Yang BB and Peng C: Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7. Mol Biol Cell 19: 4968-4979, 2008.
24. Fasanaro P, Capogrossi MC and Martelli F: Regulation of the endothelial cell cycle by the ubiquitin-proteasome system. Cardiovasc Res 85: 272-280, 2010.
25. 2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18: 629-643, 1998.
26. Gu Y, Turck CW and Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366: 707-710, 1993. (Pubitemid 24036022)
27. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993. (Pubitemid 23346377)
28. WAF1 complexes during the cell cycle. Proc Natl Acad Sci USA 95: 12254-12259, 1998.
29. Ogryzko VV, Wong P and Howard BH: WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 17: 4877-4882, 1997. (Pubitemid 27318163)